Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02486744 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population
A Phase 1 study, sponsored by Youngstown State University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02486744 is a Phase 1 study that was terminated before completion, run by Youngstown State University. The registered enrollment target is 9 participants.
The verdict
NCT02486744, a Phase 1 study, was terminated before completion, sponsored by Youngstown State University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This will be a prospective observational study of Acthar Gel in Non-Diabetic Hemodialysis \[NDHD\] patients receiving dialysis for ≤ 2 years. The project will aimed at providing proof-of-concept data that 80 U two times \[2x\] week Acthar for 6 months is a safe and effective therapy for NDHD. Effectiveness of lower dose 40 U 2X week will also be determined. Therefore the study will be a repeated measures design (Time x condition) comparison of improvement in renal function, nutritional status, quality of life and physical performance resulting from Acthar therapy.
Interventions
- DRUG Acthar Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02486744
The ClinicalTrials.gov registry entry for NCT02486744 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Youngstown State University, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acthar Gel is the first listed.
NCT02486744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02486744 about?
NCT02486744 is a clinical study titled "Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population". This will be a prospective observational study of Acthar Gel in Non-Diabetic Hemodialysis \[NDHD\] patients receiving dialysis for ≤ 2 years. The project will aimed at providing proof-of-concept data that 80 U two times \[2x\] week Acthar for 6 months is a safe and effective therapy for NDHD. Effect...
What is the current status of trial NCT02486744?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2015-03. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02486744?
The interventions under investigation include: Acthar Gel (DRUG).
Who is sponsoring clinical trial NCT02486744?
This trial is sponsored by Youngstown State University, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.